32 C
Vientiane
Wednesday, May 7, 2025
spot_img
Home Blog Page 428

ATFX Appoints Mohammad Aladham as Managing Director for Southeast Asia to Drive Regional Growth

HONG KONG, March 6, 2025 /PRNewswire/ — ATFX, a global leader in online trading, proudly announces the appointment of Mohammad Aladham as the new Managing Director for Southeast Asia. With an extensive background in fintech, brokerage expansion, and strategic leadership, Mohammad is set to drive ATFX’s growth across the region.

ATFX Appoints Mohammad Aladham as Managing Director for Southeast Asia to Drive Regional Growth
ATFX Appoints Mohammad Aladham as Managing Director for Southeast Asia to Drive Regional Growth

With over a decade of financial industry experience, Mohammad served as General Manager at Doo Group and held senior management roles at FXPRIMUS.

As ATFX continues to strengthen its presence in Southeast Asia, Mohammad will oversee market strategies, client relations, and business development initiatives. He will focus on expanding market access through strategic partnerships, enhancing client offerings with targeted marketing strategies and business growth initiatives, as well as driving regional business expansion. His deep understanding of global markets, combined with hands-on experience in marketing, sales, and brokerage expansion, positions him as a valuable asset to ATFX’s leadership team.

Commenting on his new role, Mohammad stated:

“I am excited to join ATFX and contribute to its expansion in Southeast Asia. With ATFX’s cutting-edge technology and strong global presence, we are well-positioned to serve traders with excellence.”

His appointment reinforces ATFX’s dedication to bringing top-tier talent into key markets, ensuring sustained growth and enhanced client services. With Mohammad Aladham as Managing Director, ATFX is committed to expanding market access, building strategic partnerships, and delivering an enhanced trading experience for clients across the region.

About ATFX

ATFX is a leading global fintech broker with a local presence in 23 locations and licenses from regulatory authorities including the UK’s FCA, Australian ASIC, Cypriot CySEC, UAE’s SCA, Hong Kong SFC and South African FSCA. With a strong commitment to customer satisfaction, innovative technology, and strict regulatory compliance, ATFX provides exceptional trading experiences to clients worldwide.

For further information on ATFX, please visit ATFX website https://www.atfx.com.

GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy

SUZHOU, China, March 6, 2025 /PRNewswire/ — On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received clearance from the U.S Food and Drug Administration(FDA) for its Investigational New Drug (IND) application for GEN6050X, a first-in-class base editing drug for Duchenne Muscular Dystrophy (DMD). GenAssist is planning to conduct clinical study globally for GEN6050X.

“FDA clearance of our first IND is a significant milestone for our company. It validates the ability for our Targeted AID-mediated Mutagenesis (TAM) cytosine base editor technology to target diseases previously considered untreatable—broadening the full-body application of gene editing technology. As the second generation of CRISPR-Cas9, base editors offer immense potential with significantly lower off-target risks.” said Dr. Chunyan He, CEO of GenAssist, “GenAssist is the first company to apply gene editing drug for DMD indication. By permanently repairing the mutated DMD gene, base editing may provide long-term benefit for DMD patients. We are excited about the potential of this program to bring new treatment for patients and demonstrate gene editing as a new therapeutic approach for DMD. In addition, GenAssist is advancing other DMD exon-skipping programs, which cover more than 30% DMD population.

About GEN6050X Injection

GEN6050X injection is an intravenous cytosine base editing drug designed for DMD patients amenable to exon 50 skipping. GEN6050X is based on GenAssist’s unique RNA editing-free Targeted AID-mediated Mutagenesis (TAM) cytosine base editor technology. Through one-shot systemic administration, GEN6050X may permanently restore the expression of dystrophin through editing the mutated DMD gene. It provides an alternative solution for DMD patients. The IIT study is being conducted at Peking Union Medical College Hospital (NCT06392724) since August 2024. Until now, two patients have been dosed. The first 10-year-old patient has finished six-month follow-up.

Safety Update of GEN6050X for the First two Participants Dosed:

  • The drug was safe and tolerant with only transient and manageable SAEs.
  • No SUSARs observed
  • No hospitalizations reported
  • All treatment-related AEs resolved with no sequelae
  • No AEs of hepatic transaminitis observed, including no elevated gamma-glutamyl transferase levels

Topline efficacy data from patient 001 6 months after treatment

  • 1 point improvement in North Star Ambulatory Assessment (NSAA)
  • 3 points increase in PUL2.0 scale, including 1 point increase in high level shoulder dimension and 2 points increase in mid-level elbow dimension items
  • More than 100 meters increase in 6-Minute Walk Test
  • Cardiac function keeps stable during follow up period

More data will be presented at the 2025 MDA conference.

About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is a rare, X-linked recessive hereditary disease caused by mutations in the dystrophin gene, leading to a loss of dystrophin protein vital for muscle cell membrane stability. DMD primarily affects skeletal and heart muscles, with progressive muscle wasting symptoms leading to loss of ambulation around age 12. Notably, patients reach a peak NSAA score of 26 at around 6.3 years old, after which the score declines by about 3 points per year1. As the disease advances, further complications, including heart and respiratory failure, occur, ultimately reducing the average life expectancy to about 26 years.

DMD affects approximately 1 in 3,500 to 5,000 live male births. According to LEIDEN data, about 80% of DMD patients could potentially benefit from exon skipping, with 4% specifically eligible for exon 50 skipping.

About GenAssist

GenAssist Ltd. (GenAssist) is a pioneering gene editing drug company with the operation entity located in China and subsidiaries in Boston (US) and Shanghai. The company is dedicated to developing base editing drugs against life-threatening diseases. Duchenne Muscular Disease (DMD) is the first therapeutic area.

1.F. Muntoni et al., PLoS ONE. 14, e0221097 (2019).

For more information, please visit www.genassisttx.com, Contact: xinya@genassisttx.com

Autoliv Capital Markets Day New Date: June 4, 2025

STOCKHOLM, March 6, 2025 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) and (SSE: ALIV.sdb), the worldwide leader in automotive safety systems, invites financial analysts, institutional investors, and journalists to its 2025 Capital Markets Day event, “Leading the Way”.

Autoliv invites financial analysts, institutional investors and journalists with a focus on automotive safety technology to its Capital Markets Day, on Wednesday, June 4, 2025, in Stockholm, Sweden. We are looking forward to sharing more about our journey towards our targets and how we capture growth opportunities.

The “Leading the Way” event will focus on Autoliv’s medium and long-term growth avenues, products and solutions, strategic roadmap, and progress in automation and operational efficiency. Autoliv management will present how Autoliv works strategically with OEMs, securing a strong position with future winners which will support Autoliv’s long term success.

The day will be hosted by Autoliv President & CEO, Mikael Bratt. “Leading the Way” will feature presentations from members of the Autoliv Executive Management Team, exhibitions of Autoliv’s latest innovations and technologies, and opportunities to view and try out new and exciting vehicle models from innovative vehicle manufacturers.        

Date:

June 4, 2025

Time:

Approximately 1:00 pm to 5:30pm Central European Time (TBC)

Location:

Artipelag Art Museum in the Stockholm Archipelago

Format:

Webcasted live presentations

followed by                                               

  • Meet-and-Greet with Autoliv team members
  • Experience Product Exhibition, Tech show and Customer Collaboration Exhibits including test drives
  • Boat tour to Central Stockholm for dinner at the Vasa Museum for registered guests

A formal invitation with an official agenda, registration site, and other relevant information will be released in April. Information will also later be available on the Autoliv website www.autoliv.com.                                

We look forward to welcoming you to the lovely capital city of Sweden and home of our global headquarters.

Anders Trapp

Henrik Kaar

V.P. Investor Relations

Director, Investor Relations

Autoliv, Inc.

Autoliv, Inc.

Contact details: 
Anders Trapp
Anders.Trapp@autoliv.com
+46-709578171

About Autoliv

Autoliv, Inc. (NYSE: ALV); (Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world, as well as mobility safety solutions, such as commercial vehicles and electrical safety solutions. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2024, our products saved approximately 37,000 lives and reduced around 600,000 injuries.

We have operations in 25 countries, and we drive innovation, research, and development at our 13 technical centers. Our 65,000 employees are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. Sales in 2024 amounted to $10.4 billion. For more information go to Home | Autoliv.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/autoliv/r/autoliv-capital-markets-day-new-date–june-4–2025,c4114881

The following files are available for download:

 

Thai PM Paetongtarn Shinawatra Unveils Sustainable Tourism Vision at ITB Berlin 2025

Thailand Targets High-Value, Sustainable Growth with Enhanced Infrastructure, Soft Power, and Year-Long Celebrations

BERLIN, March 6, 2025 /PRNewswire/ — Thailand’s Prime Minister, H.E. Ms. Paetongtarn Shinawatra, presented a bold vision for sustainable, high-value tourism at the Amazing Thailand Networking Event at ITB Berlin 2025. She also visited the Thailand Pavilion, marking the Tourism Authority of Thailand’s 50th anniversary at the event and highlighting the country’s Sustainable Soft Power strategy.

Thai PM Paetongtarn Shinawatra at ITB Berlin 2025, unveiling Thailand’s bold vision for sustainable, high-value tourism and inviting global travellers to experience the Amazing Thailand Grand Tourism and Sports Year 2025.
Thai PM Paetongtarn Shinawatra at ITB Berlin 2025, unveiling Thailand’s bold vision for sustainable, high-value tourism and inviting global travellers to experience the Amazing Thailand Grand Tourism and Sports Year 2025.

PM Paetongtarn reaffirmed Thailand’s commitment to sustainability, innovation, and inclusivity, inviting global travellers to join the Amazing Thailand Grand Tourism and Sports Year 2025.

The year-long celebration promises unforgettable experiences, including Thailand Summer Festivals, Maha Songkran World Water Festival, Pride Month, Loi Krathong, and the Amazing Thailand Countdown, alongside the FIVB Women’s Volleyball World Championship and SEA Games.

PM Paetongtarn underscored sustainable tourism as a key pillar of Thailand’s strategy, driving economic growth and world-class visitor experiences through initiatives that promote sustainability, seamless travel, soft power industries, medical and wellness tourism, and visitor safety.

Sustainability remains central, with Green Destinations expanding and sustainability standards strengthening. As host of the Global Sustainable Tourism Council Conference 2026, Thailand is fostering an eco-friendly tourism industry through public-private partnerships.

Thailand is streamlining visa processes, introducing an online Arrival Card, and upgrading biometric entry systems. Expanded aviation infrastructure will accommodate 250 million passengers annually, while public transport enhancements will improve connectivity to creative districts and green spaces.

Thailand’s cultural heritage and soft power boost its global tourism appeal. The Michelin Guide partnerships elevate Thai cultural identity and cuisine, while The White Lotus Season 3 has put Thailand on the map as a preferred filming location.

As ASEAN’s leading Medical and Wellness Hub, Thailand offers accredited healthcare, competitive pricing, and world-renowned hospitality. The sector, valued at €28.4 billion (THB 1 trillion), continues to expand.

Ensuring visitor safety is a government priority, with strengthened emergency response systems, enhanced security at tourist sites, and robust safety measures across all destinations.

PM Paetongtarn affirmed that these initiatives will strengthen Thailand’s position as a global leader in responsible travel, aiming for 39 million visitors and €98 billion (THB 3.5 trillion) in 2025, up from 35 million visitors and €47.40 billion (THB 1.67 trillion) in 2024.

Students Worldwide Support CNN’s #MyFreedomDay Initiative to Champion the “Freedom to Learn”

HONG KONG, March 6, 2025 /PRNewswire/ — Celebrating its laudable ninth year, #MyFreedomDay, CNN’s one-day, student-driven social media event to raise awareness of modern-day slavery, returns on March 11.

The launch of this year’s #MyFreedomDay campaign focuses on the theme of “Freedom to Learn,” which aims to raise awareness about the pressing issue of education access for children worldwide. As thousands of students prepare to participate in this year’s initiative, #MyFreedomDay seeks to create empathy and understanding about the harsh realities facing over 12 million children globally trapped in modern slavery.

Recognizing that education is a fundamental right, students involved in #MyFreedomDay will engage in activities designed to connect with the struggles of their peers who are confined in situations where learning is impossible. This year’s theme hopes to reinforce that through education, both the free and the oppressed can visualize a future where every child can learn, evolve, and break the cycle of exploitation.

This initiative empowers students across schools and communities to be advocates for education. With these series of events, conversations, and social media campaigns, the message of empathy and education equity will resonate and encourage participants to speak out for those unable to voice their aspirations for learning.

Students from more than 100 countries around the world have undertaken this year’s challenge, through presentations, panel discussions, video messages, art exhibitions, public events, and so many other meaningful activities.

#MyFreedomDay coverage will commence at 6 am HKT on March 11th in Hong Kong on CNN International, with correspondents contributing throughout the day from Hong Kong, Atlanta, London, and Sao Paulo among others.

CNN’s #MyFreedomDay microsite CNN.com/MyFreedom will offer interactive content to bolster “Freedom to Learn” and serve as educational devices for students and larger audiences worldwide.

Leif Coorlim, executive editor of the CNN Freedom Project, shared “#MyFreedomDay’s focus on the ‘Freedom to Learn’ theme reminds us that millions of children trapped in modern slavery are denied the basic right of an education. By engaging young people, we aim to foster empathy and an understanding that education is the most powerful tool we must use to break the cycles of vulnerability that lead to human trafficking. Join us in standing up for every child’s hope to learn and live in freedom.”

About The CNN Freedom Project
The CNN Freedom Project produces original reports, articles, and documentaries on human trafficking in all of its forms – from debt bondage in India to sex trafficking rings in Southern California and African slaves in the Sinai desert. Since its launch in 2011, the multi-award-winning CNN Freedom Project is among the most successful and highly visible programming initiatives on CNN International. It has generated more than 1,000 investigative stories of modern-day slavery from across six continents. Various NGOs report that these CNN Freedom Project stories have contributed to changing laws and corporate policies, led to more than 1,000 survivors receiving assistance and sparked more than $24 million in donations to anti-trafficking organizations. www.cnn.com/freedom

About CNN Worldwide
CNN Worldwide is the most honored brand in cable news, reaching more individuals on television and online than any other cable news organization in the United States. Globally, CNN International is the most widely distributed news channel. CNN Digital is the #1 online news destination, with more unique visitors and video viewers than any other news source. The award-winning portfolio of CNN includes non-scripted programming from CNN Original Series and documentary feature and short films for broadcast, streaming and distribution by CNN Films across multiple platforms. CNN programming can be found on CNN, CNN International, HLN and CNN en Español channels, on the CNN Originals hub on discovery+ on HBO Max and for pay TV subscription via CNN.com, CNN apps and cable operator platforms. Additionally, CNN Newsource is the world’s most extensively utilized news service partnering with over 1,000 local and international news organizations around the world. CNN is a division of Warner Bros. Discovery.

Conexus Studio Expands Footprint in Southeast Asia with New Offices in Bangkok and Kuala Lumpur


SINGAPORE – Media OutReach Newswire – 6 March 2025 – Conexus Studio, a leading workplace design and build firm based in Singapore, is strengthening its Southeast Asia presence with new offices in Bangkok, Thailand, and Kuala Lumpur, Malaysia. This strategic move enhances Conexus’s ability to serve clients across the region, reinforcing its reputation as a trusted partner in workplace transformation.

From left to right: Brendan Khor, Group Managing Director; Nat Jentraichan, Country Director, Thailand; Darius Chin, Country Head, Malaysia
From left to right: Brendan Khor, Group Managing Director; Nat Jentraichan, Country Director, Thailand; Darius Chin, Country Head, Malaysia

The new offices complement Conexus Studio’s Singapore headquarters, which serves as a hub for collaboration across Southeast Asia and China. The expansion allows Conexus to work more closely with businesses, providing localized expertise for clients across the region. With teams in Thailand and Malaysia, Conexus ensures tailored solutions that fit the unique needs of each market.

Brendan Khor, Group Managing Director of Conexus Studio, said: “This expansion isn’t just about growing our footprint — it’s about strengthening partnerships and delivering solutions with greater precision and relevance. It reflects our vision of building meaningful relationships and supporting clients with localized expertise and seamless service.”

A Strategic Move into Malaysia and Thailand

Darius Chin, Country Head of Malaysia, shared that growth opportunities, including Special Economic Zones and the rapidly growing data center landscape, made expansion a logical next step. “Our projects and relationships in Kuala Lumpur laid the groundwork for this move, enabling us to support businesses in creating dynamic work environments,” he added.

Nat Jentraichan, Country Director for Thailand, highlighted opportunities in Thailand’s evolving workspace design market, where businesses are increasingly prioritizing creative, people-centric office spaces. “Conexus Studio is well-positioned to contribute meaningfully to this transformation. Our goal is to create workspaces that authentically reflect the unique culture and needs of companies in Thailand,” she said.

Elevating Workplace Excellence Across Southeast Asia

The expansion represents a pivotal step in Conexus Studio’s mission to redefine workplace design and elevate industry standards across the region. This move enables Conexus to deliver bespoke solutions that meet the evolving needs of enterprise clients, reinforces the firm’s leadership in innovative design and its dedication to creating employee-centric environments that inspire collaboration, boost productivity, and reflect each market’s cultural identities. With this expansion, Conexus Studio continues to empower businesses to redefine their workspaces and thrive in a competitive global landscape.
Hashtag: #ConexusStudio, #RegionalGrowth, #BusinessExpansion, #NewLeadership, #EmployeeCentricDesign #SoutheastAsiaNews




Wechat: Conexus Studio

The issuer is solely responsible for the content of this announcement.

About Conexus Studio

Founded in March 2019, Conexus Studio is a design and build company specializing in workplaces that bring communities, aspirations, and capabilities together. The name Conexus (a portmanteau of “Connect” and “Nexus”) reflects this commitment, and our award-winning projects have been recognized for creating human-centric spaces that foster collaboration and engagement. To date, Conexus Studio has received 37 design awards, including Singapore’s SG Mark, Good Design Japan, and Asia Pacific International Property Awards, for clients such as Korn Ferry, BBC Studios, Decathlon, Hitachi, and Doctor Anywhere.

For more information, visit .

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D

  • High-speed fluorescence imaging of physiological and neuronal processes
  • Gentle long-term observation of living organisms
  • Accelerated data collection on large samples

JENA, GERMANY – Newsaktuell – 6 March 2025 – ZEISS announces the launch of Lightfield 4D, a new microscopy technology based on the light-field principle. As a new imaging mode integrated into the new ZEISS LSM 910 and LSM 990 confocal microscope systems, ZEISS Lightfield 4D redefines the way researchers observe living organisms, especially in the neurosciences, cancer research, developmental biology, and plant sciences. It enables instant volumetric high-speed imaging, allowing researchers to image the dynamic processes of life in complete samples with unprecedented temporal resolution.

ZEISS Lightfield 4D enables instant volumetric high-speed fluorescence imaging, capturing physiological and neuronal processes in 3D. Copyright: ZEISS
ZEISS Lightfield 4D enables instant volumetric high-speed fluorescence imaging, capturing physiological and neuronal processes in 3D. Copyright: ZEISS

The new technology addresses the critical need for 4D imaging – combining volume and time to truly understand biological processes. Traditional optical sectioning techniques that rely on sequential image acquisition to create Z-stack images have long struggled with the limitations of sequential image acquisition, which introduces time delays and compromises the spatiotemporal accuracy of data. ZEISS Lightfield 4D overcomes these challenges by imaging entire 3D data sets at a precise moment in time, eliminating time delays within a captured volume.

Accelerating microscopic imaging: One snap, one volume

Utilizing a micro lens array, ZEISS Lightfield 4D generates 37 individual images simultaneously, capturing comprehensive 3D information in real-time. This innovative approach allows for the creation of Z-stacks through advanced deconvolution-based processing, achieving an impressive rate of up to 80 volume Z-stacks per second, providing insights into rapid biological events such as physiological and neuronal processes.

Improving biological insight with speed and gentleness

A complete Z-stack is captured in one illumination event. This reduces light exposure and phototoxic effects. It allows for long-term imaging of entire living organisms at high temporal density, following biological processes over long periods of time. The unmatched speed of ZEISS Lightfield 4D facilitates the capture of multi-color volumes of large samples, enhancing productivity of experiments across various applications.

“Combining volume and time to enhance our understanding of complex biological processes, ZEISS Lightfield 4D represents a leap forward in 4D imaging,” says Dr. Bernhard Zimmermann, Head of Life Sciences Microscopy at ZEISS. “We believe that Lightfield 4D will redefine the imaging landscape. This innovative system empowers researchers to capture biological processes in real-time, providing unprecedented insights into the dynamic nature of life.”

New LSM platforms

The combination of the remarkable imaging flexibility of laser scanning microscopes (LSMs) and the gentle and instant volume imaging capabilities of ZEISS Lightfield 4D enables previously impossible experiments and pushes scientific research to new frontiers.

In conjunction with the launch of Lightfield 4D, ZEISS introduces enhanced versions of its LSM platforms: ZEISS LSM 910 and LSM 990. These upgraded systems feature new high-bandwidth electronics that support beampath technology for exceptional light preservation, visualization of high dynamic ranges, and a broad wavelength bandwidth. Additionally, image quality improvements with ZEISS Airyscan jDCV are now available for all Airyscan Multiplex modes. With the help of the Microscopy Copilot, a personal AI assistant, researchers can interactively explore new possibilities for their imaging experiments.

For more information, please visit: https://zeiss.ly/nw-lightfield-4d

Hashtag: #ZEISS

The issuer is solely responsible for the content of this announcement.

Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine

  • The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest’s proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials.
  • In preclinical studies, EVM16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability.
  • Preclinical data also showed a synergistic anti-tumor effect when EVM16 was combined with a PD-1 antibody, supporting its potential use in combination therapies in clinical settings.

SHANGHAI, March 6, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been dosed with the Company’s internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT) EVM16CX01. EVM16CX01 is the first-in-human (FIH) trial for EVM16, conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer center, to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in patients with advanced or recurrent solid tumors.

EVM16 is a novel personalized therapeutic mRNA cancer vaccine internally developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor mutations of each patient using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. The vaccine is designed to encode dozens of tumor neoantigens. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.

In preclinical studies, vaccination with EVM16 stimulated a strong neoantigen-specific T cell response in different mouse models and showed significant tumor growth inhibition in the syngeneic B16F10 mouse melanoma model. EVER-NEO-1, the AI-based neoantigen prediction algorithm developed in-house by Everest, can identify the majority of reported tumor neoantigens, as well as several previously unreported neoantigens. Furthermore, the neoantigen prediction capability of EVER-NEO-1 was shown to be either comparable to or superior to leading industry algorithms in multiple independent validation studies.

Preclinical data also demonstrated that the combination of EVM16 and a PD-1 antibody has synergistic effects, which supports the combination of EVM16 with checkpoint inhibitors in clinical settings. In preclinical toxicity studies, repeated dosing with EVM16 was well tolerated and safe. Taken together, the preclinical studies show that EVM16 is safe and efficacious and has potential to bring benefits to cancer patients. 

“The first patient dosed with the personalized mRNA cancer vaccine EVM16 represents a notable milestone in its clinical development. EVM16 is a customized vaccine based on each patient’s tumor-specific mutations, and using the cutting-edge mRNA technology, to activate the patient’s tumor-specific immune response to recognize and attack tumor cells.” said Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology. ” In preclinical studies, we are excited to discover that EVM16, when combined with PD-1 antibodies, demonstrated synergistic anti-tumor effects, further highlighting its broader potential for clinical application. We are confident in achieving positive outcomes in the upcoming clinical trials, bringing hope to cancer patients.”

“In recent years, AI has become a major force in drug development, especially in the area of mRNA vaccines. AI is increasingly seen as a crucial tool for boosting research efficiency and accuracy, attracting substantial attention from both the biopharmaceutical industry and governments worldwide. Everest has demonstrated the clinical validation capabilities of its mRNA platform since 2021, with an emphasis on employing AI to identify tumor neoantigens. By continually optimizing its algorithms, the company has enhanced the precision of neoantigen recognition and validation, giving it a strong foundation and a competitive edge in developing mRNA-based cancer vaccines.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “EVM16 is the first personalized mRNA cancer vaccine internally developed by Everest. The first patient dosing marks a significant milestone in its clinical development of EVM16, indicating our proprietary tumor neoantigen AI-based algorithm system and mRNA technology platform have advanced to human trials. As a cancer vaccine candidate developed using our proprietary mRNA platform, we look forward to demonstrating EVM16’s therapeutic potential in upcoming clinical trials, with the goal of offering innovative treatment options to cancer patients worldwide and expand choices for those facing life-threatening diseases.”

According to the Globocan’s data in 2022, there were 19.976 million new cancer cases globally, with 9.744 million cancer-related deaths1. Immunotherapy including checkpoint inhibitors has become an important part of treating some cancer types. However, they are only effective for some patients, and there is an urgent need to develop new generations of immunotherapies, such as personalized mRNA cancer vaccines, that have demonstrated early promise in clinical setting.  

Everest Medicines is currently developing a range of mRNA cancer therapeutics, including personalized cancer vaccines (PCVs), tumor-associated antigen (TAA) vaccines, immunomodulatory cancer vaccines, etc. Additionally, the company is working on next-generation lipid nanoparticle (LNP) delivery systems to enhance cell-mediated immune responses.  Everest Medicines will submit an investigational new drug application for its TAA vaccines in China and the United States in 2025.

About EVM16

EVM16 is a novel personalized mRNA cancer vaccine independently developed by Everest Medicines. EVM16 contains neoantigens with high immunogenicity potential and predicted by Everest-proprietary algorithm EVER-NEO-1 and uses an LNP delivery system to efficiently deliver neoantigen-expressing mRNAs into the human body. After vaccination with EVM16, neoantigens-encoding mRNAs are delivered into human body to produce neoantigen peptides, which activate neoantigen-specific T cell immune responses to kill tumor cells, thereby inhibiting tumor growth.

About EVM16CX01 study

The study is a FIH, dose escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and initial efficacy of EVM16 injection as a single and in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors. The primary objectives are to evaluate the safety and tolerability of EVM16 monotherapy and EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors, and to determine the recommended phase 2 dose (RP2D) of EVM16. The secondary objectives are to evaluate the immunogenicity of EVM16, and the initial efficacy of EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Reference:

1.     Globocan 2022: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf